Abstract：
OBJECTIVE: Evaluation of the effectiveness of pneumatic vitreolysis in disrupting vitreomacular traction in our own cohort of patients.
METHODS: Prospective follow-up of 21 eyes of 18 patients with focal VMT (adhesion width < 1500 µm) who underwent intravitreal injection of 0.3 ml of 100% perfluoropropane between January 2015 and December 2020. The patients were observed for 90 days.
RESULTS: Release of VMT was achieved on the 28th day of observation in 15 out of 21 eyes (71.4%), and by the 90th day in 19 out of 21 eyes (90.5%). The average width of adhesion in our patients was 382 µm (±212 µm). Average best corrected visual acuity in our cohort was initially 0.77 (±0.21), after 28 days 0.74 (±0.30), and after 3 months 0.82 (±0.21). At the end of the follow-up period, we did not observe a statistically significant improvement in vision. Macular holes developed in two eyes, but spontaneously closed within 1 month of observation, and no more complications were observed in the cohort.
CONCLUSIONS: Pneumatic vitreolysis by intravitreal injection of C3F8 gas is an effective and inexpensive option for the management of symptomatic vitreomacular traction. The incidence of serious adverse events in our follow-up was significantly lower than in recently published series. The method of management should be selected individually according to the parameters of adhesion, macular hole and associated ocular pathologies.
METHODS: Prospective follow-up of 21 eyes of 18 patients with focal VMT (adhesion width < 1500 µm) who underwent intravitreal injection of 0.3 ml of 100% perfluoropropane between January 2015 and December 2020. The patients were observed for 90 days.
RESULTS: Release of VMT was achieved on the 28th day of observation in 15 out of 21 eyes (71.4%), and by the 90th day in 19 out of 21 eyes (90.5%). The average width of adhesion in our patients was 382 µm (±212 µm). Average best corrected visual acuity in our cohort was initially 0.77 (±0.21), after 28 days 0.74 (±0.30), and after 3 months 0.82 (±0.21). At the end of the follow-up period, we did not observe a statistically significant improvement in vision. Macular holes developed in two eyes, but spontaneously closed within 1 month of observation, and no more complications were observed in the cohort.
CONCLUSIONS: Pneumatic vitreolysis by intravitreal injection of C3F8 gas is an effective and inexpensive option for the management of symptomatic vitreomacular traction. The incidence of serious adverse events in our follow-up was significantly lower than in recently published series. The method of management should be selected individually according to the parameters of adhesion, macular hole and associated ocular pathologies.
摘要：
目的：在我们自己的患者队列中评估气压玻璃体溶解术在破坏玻璃体牵引中的有效性。
方法：在2015年1月至2020年12月期间，对18例局灶性VMT（粘连宽度<1500µm）患者的21只眼进行前瞻性随访。观察患者90天。
结果：在观察的第28天，21只眼中有15只（71.4％）实现了VMT的释放，到第90天，21只眼睛中有19只(90.5%)。我们患者的平均粘连宽度为382µm（±212µm）。我们队列中的平均最佳矫正视力最初为0.77（±0.21），28天后0.74（±0.30），3个月后0.82(±0.21)。在随访期结束时，我们没有观察到视力的显著改善.两只眼睛出现黄斑裂孔，但在观察后1个月内自发关闭，并且在队列中未观察到更多的并发症。
结论：玻璃体内注射C3F8气体气动玻璃体溶解术是治疗有症状的玻璃体黄斑牵引的一种有效且廉价的选择。在我们的随访中，严重不良事件的发生率明显低于最近发表的系列。管理方法应根据附着力参数单独选择，黄斑裂孔和相关眼病。
方法：在2015年1月至2020年12月期间，对18例局灶性VMT（粘连宽度<1500µm）患者的21只眼进行前瞻性随访。观察患者90天。
结果：在观察的第28天，21只眼中有15只（71.4％）实现了VMT的释放，到第90天，21只眼睛中有19只(90.5%)。我们患者的平均粘连宽度为382µm（±212µm）。我们队列中的平均最佳矫正视力最初为0.77（±0.21），28天后0.74（±0.30），3个月后0.82(±0.21)。在随访期结束时，我们没有观察到视力的显著改善.两只眼睛出现黄斑裂孔，但在观察后1个月内自发关闭，并且在队列中未观察到更多的并发症。
结论：玻璃体内注射C3F8气体气动玻璃体溶解术是治疗有症状的玻璃体黄斑牵引的一种有效且廉价的选择。在我们的随访中，严重不良事件的发生率明显低于最近发表的系列。管理方法应根据附着力参数单独选择，黄斑裂孔和相关眼病。
